Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc by (c) Johansson, Patricia et al, 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/201180

Epigenome-wide analysis of T-cell large granular lymphocytic leukemia identifies BCL11B as a potential biomarker

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Background: The molecular pathogenesis of T-cell large granular lymphocytic leukemia (T-LGLL), a mature T-cell leukemia arising commonly from T-cell receptor alpha beta-positive CD8(+) memory cytotoxic T cells, is only partly understood. The role of deregulated methylation in T-LGLL is not well known. We analyzed the epigenetic profile of T-LGLL cells of 11 patients compared to their normal counterparts by array-based DNA methylation profiling. For identification of molecular events driving the pathogenesis of T-LGLL, we compared the differentially methylated loci between the T-LGLL cases and normal T cells with chromatin segmentation data of benign T cells from the BLUEPRINT project. Moreover, we analyzed gene expression data of T-LGLL and benign T cells and validated the results by pyrosequencing in an extended cohort of 17 patients, including five patients with sequential samples. Results: We identified dysregulation of DNA methylation associated with altered gene expression in T-LGLL. Since T-LGLL is a rare disease, the samples size is low. But as confirmed for each sample, hypermethylation of T-LGLL cells at various CpG sites located at enhancer regions is a hallmark of this disease. The interaction of BLC11B and C14orf64 as suggested by in silico data analysis could provide a novel pathogenetic mechanism that needs further experimental investigation. Conclusions: DNA methylation is altered in T-LGLL cells compared to benign T cells. In particular, BCL11B is highly significant differentially methylated in T-LGLL cells. Although our results have to be validated in a larger patient cohort, BCL11B could be considered as a potential biomarker for this leukemia. In addition, altered gene expression and hypermethylation of enhancer regions could serve as potential mechanisms for treatment of this disease. Gene interactions of dysregulated genes, like BLC11B and C14orf64, may play an important role in pathogenic mechanisms and should be further analyzed.

Matèries (anglès)

Citació

Citació

JOHANSSON, Patricia, LAGUNA, Teresa, OSSOWSKI, Julio, PANCALDI, Vera, BRAUSER, Martina, DÜHRSEN, Ulrich, KEUNEKE, Lara, QUEIRÓS, Ana c., RICHTER, Julia, MARTÍN-SUBERO, José ignacio, SIEBERT, Reiner, SCHLEGELBERGER, Brigitte, KÜPPERS, Ralf, DÜRIG, Jan, MURGA PENAS, Eva m., CARILLO DE SANTA PAU, Enrique, BERGMANN, Anke k.. Epigenome-wide analysis of T-cell large granular lymphocytic leukemia identifies BCL11B as a potential biomarker. _Clinical Epigenetics_. 2022. Vol. 14, núm. 1. [consulta: 23 de gener de 2026]. ISSN: 1868-7083. [Disponible a: https://hdl.handle.net/2445/201180]

Exportar metadades

JSON - METS

Compartir registre